MYC and cancer: Recent findings from two separate studies have shown that knockdown of LZTS2 expression sensitizes cells to paclitaxel therapy in addition to antagonizing proliferation of several cancer cell lines by down-regulation of myc and cyclin D1 through engagement of the NF-κB pathway [30], [31].